{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:18:07Z","timestamp":1768216687805,"version":"3.49.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Treatment approaches to childhood T-cell lymphoblastic lymphoma (T-LL) are based on those used for T-cell acute lymphoblastic leukemia (T-ALL), but reports of outcomes with contemporary regimens are limited, as patients with LL are often excluded from ALL clinical trials. In this study, we retrospectively analyzed the characteristics and outcome of a cohort of 23 pediatric patients with T-LL treated between 2006 and 2020 according to Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols. Five-year event-free survival, overall survival, and disease-free survival rates were 78.3% (95% CI: 55.4%\u201390.3%), 87.0% (95% CI: 64.8%\u201395.6%), and 90% (95% CI: 65.6%\u201397.4%), respectively. Morphological marrow disease (defined as 5%\u201324% blasts) at diagnosis was the only feature associated with adverse prognosis. Treatment based on DFCI ALL protocols is an effective strategy for childhood LL and should be considered at the time of treatment selection.<\/jats:p>","DOI":"10.3389\/fped.2025.1686081","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:14:54Z","timestamp":1768205694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of T-cell lymphoblastic lymphoma in children and adolescents treated with Dana-Farber Cancer Institute Childhood ALL Consortium protocols"],"prefix":"10.3389","volume":"13","author":[{"given":"Giacomo","family":"Gotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Flamand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Testa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thai-Hoa","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Athale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew E.","family":"Place","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bjh.14017","article-title":"Current status and future directions of T-lymphoblastic lymphoma in children and adolescents","volume":"173","author":"Burkhardt","year":"2016","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1182\/blood.V95.2.416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.2005.02.2707","article-title":"Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system\u2013negative stage III or IV lymphoblastic lymphoma","volume":"24","author":"Burkhardt","year":"2006","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","article-title":"Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma","volume":"102","author":"Landmann","year":"2017","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children's Oncology Group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/pbc.22162","article-title":"Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of Pediatric Hematology and Oncology","volume":"53","author":"Pillon","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/annonc\/mdt221","article-title":"Results of treatment of advanced-stage lymphoblastic lymphoma at St Jude Children\u2019s Research Hospital from 1962 to 2002","volume":"24","author":"Sandlund","year":"2013","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/bloodadvances.2018016584","article-title":"Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL consortium protocol 05-001","volume":"2","author":"Vrooman","year":"2018","journal-title":"Blood Adv"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/JCO.20.03692","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman","year":"2021","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06629-y","article-title":"Paediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland","author":"Trinquand","year":"2025","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1200\/JCO.2008.21.1318","article-title":"Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children\u2019s oncology group","volume":"27","author":"Coustan-Smith","year":"2009","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1002\/pbc.25607","article-title":"Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: the AIEOP experience","volume":"62","author":"Mussolin","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood.2023021184","article-title":"MRD At the end of induction and EFS in T-cell lymphoblastic lymphoma: children\u2019s oncology group trial AALL1231","volume":"143","author":"Hayashi","year":"2024","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1007\/s00277-025-06535-3","article-title":"Prognostic value of dynamic minimal residual disease monitoring for adolescent and adult T-lymphoblastic leukemia\/lymphoma","volume":"104","author":"Yang","year":"2025","journal-title":"Ann Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1182\/blood.2024024344","article-title":"MRD: also for T-lymphoblastic lymphoma","volume":"143","author":"Ribera","year":"2024","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1182\/blood-2012-12-474148","article-title":"Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence","volume":"121","author":"Bonn","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2020005381","article-title":"Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance","volume":"137","author":"Khanam","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"JCO.21.02678","DOI":"10.1200\/JCO.21.02678","article-title":"Children\u2019s oncology group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/bjh.12460","article-title":"Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the children\u2019s oncology group","volume":"162","author":"Termuhlen","year":"2013","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e28719","DOI":"10.1002\/pbc.28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL consortium protocols 05-001 and 11-001","volume":"68","author":"Burns","year":"2021","journal-title":"Pediatr Blood Cancer"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1686081\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:14:56Z","timestamp":1768205696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1686081\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":23,"alternative-id":["10.3389\/fped.2025.1686081"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1686081","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1686081"}}